Cebrotonin Side Effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The assessment of side effects is based on the following frequencies: Very common: may affect more than 1 in 10 people / Common: may affect up to 1 in 10 people / Uncommon: may affect up to 1 in 100 people / Rare: may affect up to 1 in 1,000 people / Very rare: may affect up to 1 in 10,000 people / Not known: frequency cannot be estimated from the available data.
Blood and lymphatic system disorders: not known: hemorrhagic disease.
Immune system disorders: very rare: allergic reactions such as anaphylactic reactions; not known: hypersensitivity.
Metabolism and nutrition disorders: Common: weight gain.
Psychiatric disorders: Common: increased psychomotor activity, nervousness, aggressiveness, disturbed sleep, insomnia, depressive mood, anxiety, Uncommon: depression; very rare: states of confusion, hallucinations.
Nervous system disorders: Common: Excessive motor activity (hyperkinesia); uncommon: drowsiness (somnolence); very rare: headaches, disturbances in the interaction of movements (ataxia), impaired balance; not known: exacerbation of epilepsy, sleeping disorders.
Ear and labyrinth disorders: uncommon: Dizziness.
Vascular disorders: uncommon: blood pressure reduction or enhancement.
Gastrointestinal disorders: Common: gastrointestinal discomfort (abdominal discomfort), diarrhea, nausea, vomiting; not known: abdominal pain, upper abdominal pain, dry mouth, increased salivation.
Skin and subcutaneous tissue disorders: very rare: Skin redness and flushing, sweating, itching, hives (urticaria); not known: Painful swelling of the skin and mucous membranes (Oedema Quincke's), inflammatory skin reaction (dermatitis).
General disorders and administration site conditions: uncommon: Weakness or loss of strength (asthenia), increased sex drive (libido increase), increased sexuality.
Hint: The desired synchronisation and support of the electric activity of the brain can in exceptional cases lead to a decrease in the convulsion threshold in specially disposed patients (neuronal hyperexcitability). It should be taken care that patients who need anticonvulsants maintain this therapy even if the treatment with this product results in a subjective improvement.
At the first sign of a hypersensitivity reaction CEBROTONIN 800 mg must not be taken once again.